How Do 5-Alpha-Reductase Inhibitors Change PSA Density in Patients on Active Surveillance?

    L.A. Webb, Gabriela M. Diaz, Syed N. Rahman … Preston Sprenkle
    Studysummary This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on auajournals.org →
    Discuss this study in the Community →

    Related research 5

    1. 5-Alpha Reductase Inhibitors in Androgenetic Alopecia: Shifting Paradigms, Current Concepts, Comparative Efficacy, and Safety Dermatologic Therapy · 2020
    2. What Do We Know About 5-Alpha Reductase Inhibitors? Surgical and Cosmetic Dermatology · 2018
    3. Atypical Post-Finasteride Syndrome: A Pharmacological Riddle Indian Journal of Pharmacology · 2016
    4. Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-Alpha Reductase Inhibitors Daehan namseong gwahag hoeji · 2012
    5. 5 Alpha-Reductase Inhibitors: What's New? Current opinion in urology · 2003